Academic Journal
Chimeric PD‑1 receptor redirects primary T cells against childhood solid tumors but not to PD‑1 ligand‑positive CD80‑coexpressing cells.
| Τίτλος: | Chimeric PD‑1 receptor redirects primary T cells against childhood solid tumors but not to PD‑1 ligand‑positive CD80‑coexpressing cells. |
|---|---|
| Συγγραφείς: | Shin C; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Imamura M; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Kasahara Y; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Suzuki Y; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Baba M; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Kubo N; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Hosokai R; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Iwabuchi H; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Murayama Y; Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Kawashima H; Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Ogose A; Department of Orthopedic Surgery, Uonuma Kikan Hospital, Minamiuonuma, Niigata 949‑7302, Japan., Mihara K; International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Aichi 470‑1192, Japan., Saitoh A; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan., Imai C; Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951‑8510, Japan. |
| Πηγή: | Molecular medicine reports [Mol Med Rep] 2025 Sep; Vol. 32 (3). Date of Electronic Publication: 2025 Jul 11. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Athens, Greece : D. A. Spandidos |
| Ιατρικοί όροι (MeSH): | T-Lymphocytes*/immunology , T-Lymphocytes*/metabolism , Neoplasms*/therapy , Neoplasms*/immunology , B7-H1 Antigen*/metabolism , B7-H1 Antigen*/immunology , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/genetics , Programmed Cell Death 1 Receptor*/metabolism , Receptors, Chimeric Antigen*/immunology , Receptors, Chimeric Antigen*/metabolism , Receptors, Chimeric Antigen*/genetics , B7-1 Antigen*/metabolism , B7-1 Antigen*/immunology , B7-1 Antigen*/genetics, Immunotherapy, Adoptive/methods ; Programmed Cell Death 1 Ligand 2 Protein/immunology ; Programmed Cell Death 1 Ligand 2 Protein/metabolism ; Humans ; Child ; Female ; Male ; Cell Line, Tumor ; Child, Preschool |
| Περίληψη: | The clinical application of T cells engineered with chimeric antigen receptors (CARs) for solid tumors is challenging. A major reason for this involves tumor immune evasion mechanisms, including the high expression of immune checkpoint molecules, such as the programmed death 1 (PD‑1) ligands PD‑L1 and PD‑L2. The inducible expression of PD‑L1 in tumors has been observed after CAR‑T‑cell infusion, even in tumors natively not expressing PD‑L1. Furthermore, numerous types of pediatric cancer do not have suitable targets for CAR‑T‑cell therapy. Therefore, the present study aimed to develop novel CAR‑T cells that target PD‑L1 and PD‑L2, and to evaluate their efficacy against pediatric solid tumors. A novel CAR harboring the immunoglobulin V‑set domain of the human PD‑1 receptor as an antigen binding site (PD‑1 CAR‑T) was developed without using a single‑chain variable fragment. PD‑1 CAR‑T cells were successfully manufactured by adding an anti‑PD‑1 antibody, nivolumab, to the ex vivo expansion culture to prevent fratricide during the manufacturing process due to the inducible expression of PD‑L1 in activated human T cells. The expression of PD‑L1 (and PD‑L2 to a lesser extent) was revealed to be highly upregulated in various pediatric solid tumor cells, which displayed no or very low expression initially, on in vitro exposure to interferon‑γ and/or tumor necrosis factor‑α, which are cytokines secreted by tumor‑infiltrating T cells. Furthermore, PD‑1 CAR-T cells exhibited strong cytotoxic activity against pediatric solid tumor cells expressing PD‑L1 and PD‑L2. Conversely, the effect of PD‑1 CAR‑T cells was significantly attenuated against PD‑L1‑positive cells coexpressing CD80, suggesting that the toxicity of PD‑1 CAR‑T cells to normal immune cells, including antigen presenting cells, can be minimized. In conclusion, PD‑1 ligands are promising therapeutic targets for pediatric solid tumors. PD‑1 CAR‑T cells, either alone or in combination with CAR‑T cells with other targets, represent a potential treatment option for solid tumors. |
| References: | N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370) Front Immunol. 2019 Nov 12;10:2664. (PMID: 31798590) Mol Ther Oncolytics. 2022 Feb 20;24:849-863. (PMID: 35317524) Cancer Immunol Res. 2014 Jul;2(7):690-698. (PMID: 24866169) Nat Biotechnol. 2018 Oct;36(9):847-856. (PMID: 30102295) Cancers (Basel). 2023 Jul 19;15(14):. (PMID: 37509328) Mol Immunol. 2020 May 6;122:200-206. (PMID: 32388482) J Immunother Cancer. 2022 Jul;10(7):. (PMID: 35793866) Nat Med. 2021 Aug;27(8):1419-1431. (PMID: 34312556) Clin Cancer Res. 2013 Oct 15;19(20):5636-46. (PMID: 23873688) J Clin Oncol. 2023 Mar 20;41(9):1670-1683. (PMID: 36346962) Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573) N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797) J Transl Med. 2023 Mar 22;21(1):213. (PMID: 36949487) Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375) Science. 2019 May 10;364(6440):558-566. (PMID: 31000591) Lancet Oncol. 2020 Apr;21(4):541-550. (PMID: 32192573) Cancer Discov. 2021 Nov;11(11):2748-2763. (PMID: 34266984) Cancer Res. 2016 Mar 15;76(6):1578-90. (PMID: 26979791) J Immunother Cancer. 2020 May;8(1):. (PMID: 32439799) Oncoimmunology. 2015 Jul 15;5(1):e1064578. (PMID: 26942080) Nat Commun. 2021 Feb 8;12(1):868. (PMID: 33558511) Br J Haematol. 2010 Oct;151(1):37-46. (PMID: 20678160) J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297) Leukemia. 2004 Apr;18(4):676-84. (PMID: 14961035) Bone Marrow Transplant. 2013 Mar;48(3):452-8. (PMID: 23208313) Sci Adv. 2022 Nov 25;8(47):eadd1187. (PMID: 36417514) Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. (PMID: 28912137) Mol Ther Oncol. 2024 Oct 05;32(4):200891. (PMID: 39498357) Haematologica. 2018 May;103(5):e215-e218. (PMID: 29419431) Immunology. 2017 Nov;152(3):472-483. (PMID: 28670716) N Engl J Med. 2023 Mar 16;388(11):1002-1014. (PMID: 36762851) Blood. 2022 Feb 17;139(7):1026-1038. (PMID: 34496014) Pediatr Blood Cancer. 2016 Aug;63(8):1461-4. (PMID: 27135656) Lancet Oncol. 2020 Jan;21(1):121-133. (PMID: 31812554) Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870) Hematol Oncol Stem Cell Ther. 2014 Mar;7(1):1-17. (PMID: 24398144) N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407) N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173) |
| Contributed Indexing: | Keywords: CD80; PD‑1; PD‑1 ligands; childhood solid tumors; fratricide |
| Substance Nomenclature: | 0 (B7-H1 Antigen) 0 (Programmed Cell Death 1 Receptor) 0 (Receptors, Chimeric Antigen) 0 (B7-1 Antigen) 0 (CD274 protein, human) 0 (Programmed Cell Death 1 Ligand 2 Protein) 0 (PDCD1 protein, human) |
| Entry Date(s): | Date Created: 20250711 Date Completed: 20250711 Latest Revision: 20250720 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12272151 |
| DOI: | 10.3892/mmr.2025.13608 |
| PMID: | 40641108 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1791-3004 |
|---|---|
| DOI: | 10.3892/mmr.2025.13608 |